Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of PRX-03140 as Monotherapy in Subjects With Alzheimer's Disease

NCT00693004 is registered in ClinicalTrials.gov with Epix Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00693004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00693004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of PRX-03140 as Monotherapy in Subjects With Alzheimer's Disease
Lead sponsor
Epix Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2008
Completion date
Not reported
Enrollment
236 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease